Debiopharm acquires FibroTrap sample processing technology from Spinomix
Fibrinogen-based technology allows the highly specific separation and efficient concentration of target molecules from liquid samples
Debiopharm International, part of Debiopharm Group, and Spinomix, a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, have announced the acquisition by Debiopharm of Spinomix’s FibroTrap sample processing technology. Commercial terms of the transaction were not disclosed.
FibroTrap is a fibrinogen-based technology allowing the highly specific separation and efficient concentration of target molecules from liquid samples within a simple, routine sample-collection tube.
This technology greatly simplifies the sample processing workflow, improves sensitivity and significantly shortens the time taken from sample collection to obtaining results. FibroTrap is applicable to a wide variety of matrices (blood, urine, swabs, food, etc.) to isolate a large spectrum of targets, including bacteria, viruses and tumour cells, and hence could provide a breakthrough in sample processing applied to clinical diagnostics and the food industry.
‘This agreement reflects our long-held strategy to develop our technologies to a certain maturity before finding the best commercialisation partner,’ stated Heiner Dreismann, Chairman of the Board. ‘We are delighted to have transferred FibroTrap to Debiopharm, who will now continue with the development of FibroTrap technology, take it to market and realise its full potential in many different applications.’
‘The team at Spinomix is very proud to have developed this novel technology, which will greatly improve the sensitivity and time taken to diagnose samples by doctors and laboratories. This will undoubtedly pave the way to a new era in molecular diagnostics in which patients will benefit enormously from an enhanced process,’ said Nasri Nahas, Chief Executive Officer.
